Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 5
1997 6
1998 1
1999 3
2000 5
2001 5
2002 3
2003 3
2004 2
2005 4
2006 2
2007 6
2008 2
2009 3
2010 1
2011 2
2012 6
2013 2
2014 9
2015 3
2016 3
2017 2
2018 5
2019 5
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

92 results
Results by year
Filters applied: . Clear all
Page 1
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.
Panni RZ, Herndon JM, Zuo C, Hegde S, Hogg GD, Knolhoff BL, Breden MA, Li X, Krisnawan VE, Khan SQ, Schwarz JK, Rogers BE, Fields RC, Hawkins WG, Gupta V, DeNardo DG. Panni RZ, et al. Among authors: rogers be. Sci Transl Med. 2019 Jul 3;11(499):eaau9240. doi: 10.1126/scitranslmed.aau9240. Sci Transl Med. 2019. PMID: 31270275 Free PMC article.
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
Hegde S, Krisnawan VE, Herzog BH, Zuo C, Breden MA, Knolhoff BL, Hogg GD, Tang JP, Baer JM, Mpoy C, Lee KB, Alexander KA, Rogers BE, Murphy KM, Hawkins WG, Fields RC, DeSelm CJ, Schwarz JK, DeNardo DG. Hegde S, et al. Among authors: rogers be. Cancer Cell. 2020 Mar 16;37(3):289-307.e9. doi: 10.1016/j.ccell.2020.02.008. Cancer Cell. 2020. PMID: 32183949
Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Dehdashti F, et al. Among authors: rogers be. Breast Cancer Res Treat. 2018 Jun;169(3):523-530. doi: 10.1007/s10549-018-4696-z. Epub 2018 Feb 13. Breast Cancer Res Treat. 2018. PMID: 29442264 Free PMC article.
Copper import in Escherichia coli by the yersiniabactin metallophore system.
Koh EI, Robinson AE, Bandara N, Rogers BE, Henderson JP. Koh EI, et al. Among authors: rogers be. Nat Chem Biol. 2017 Sep;13(9):1016-1021. doi: 10.1038/nchembio.2441. Epub 2017 Jul 24. Nat Chem Biol. 2017. PMID: 28759019 Free PMC article.
CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia.
Muz B, Bandara N, Mpoy C, Sun J, Alhallak K, Azab F, Rogers BE, Azab AK. Muz B, et al. Among authors: rogers be. Cancer Biol Ther. 2020;21(1):52-60. doi: 10.1080/15384047.2019.1665405. Epub 2019 Oct 1. Cancer Biol Ther. 2020. PMID: 31571524 Free PMC article.
Alteration of Cellular Reduction Potential Will Change 64Cu-ATSM Signal With or Without Hypoxia.
Floberg JM, Wang L, Bandara N, Rashmi R, Mpoy C, Garbow JR, Rogers BE, Patti GJ, Schwarz JK. Floberg JM, et al. Among authors: rogers be. J Nucl Med. 2020 Mar;61(3):427-432. doi: 10.2967/jnumed.119.230805. Epub 2019 Oct 4. J Nucl Med. 2020. PMID: 31586008 Free PMC article.
PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo.
Kapoor V, Singh AK, Rogers BE, Thotala D, Hallahan DE. Kapoor V, et al. Among authors: rogers be. J Control Release. 2019 Mar 28;298:194-201. doi: 10.1016/j.jconrel.2019.02.008. Epub 2019 Feb 11. J Control Release. 2019. PMID: 30763622 Free PMC article.
Aerosol-synthesized siliceous nanoparticles: impact of morphology and functionalization on biodistribution.
Diebolder P, Vazquez-Pufleau M, Bandara N, Mpoy C, Raliya R, Thimsen E, Biswas P, Rogers BE. Diebolder P, et al. Among authors: rogers be. Int J Nanomedicine. 2018 Nov 12;13:7375-7393. doi: 10.2147/IJN.S177350. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30519021 Free PMC article.
Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.
Bandara N, Jacobson O, Mpoy C, Chen X, Rogers BE. Bandara N, et al. Among authors: rogers be. Bioconjug Chem. 2018 Jul 18;29(7):2448-2454. doi: 10.1021/acs.bioconjchem.8b00341. Epub 2018 Jul 2. Bioconjug Chem. 2018. PMID: 29927587
Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer.
Bandara N, Stott Reynolds TJ, Schehr R, Bandari RP, Diebolder PJ, Krieger S, Xu J, Miao Y, Rogers BE, Smith CJ. Bandara N, et al. Among authors: rogers be. Nucl Med Biol. 2018 Jul-Aug;62-63:71-77. doi: 10.1016/j.nucmedbio.2018.06.001. Epub 2018 Jun 8. Nucl Med Biol. 2018. PMID: 29929115 Free PMC article.
92 results
Jump to page
Feedback